Inozyme Pharma, Inc.
INZY
$1.26
-$0.23-15.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -25.67% | -47.67% | -73.48% | -34.15% | -16.18% |
| Total Depreciation and Amortization | -15.31% | -6.25% | -10.05% | -12.08% | 5.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,559.74% | 252.69% | 32.47% | -101.81% | -105.17% |
| Change in Net Operating Assets | 98.80% | 34.67% | 327.26% | 36.73% | 19.10% |
| Cash from Operations | -3.79% | -30.00% | -52.16% | -38.04% | -28.38% |
| Capital Expenditure | 83.81% | -85.71% | 100.00% | 81.71% | -128.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 342.84% | 152.37% | 209.19% | -25.21% | -295.01% |
| Cash from Investing | 338.64% | 152.33% | 209.12% | -24.50% | -301.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,512.50% | -84.91% | -97.16% | 65.63% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.94% | -84.91% | -98.06% | -99.21% | -- |
| Foreign Exchange rate Adjustments | -102.99% | 99.45% | -109.09% | -47.37% | 152.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.61% | 54.41% | 34.50% | -186.72% | -10.58% |